BioTek Instruments, Inc., today announced the winner of the "Win an Epoch" contest, which ran April 15 - September 17, 2010 in the United Kingdom. The prize, BioTek's Epoch^TM Multi-Volume Spectrophotometer System, is awarded in cooperation with Fisher Scientific. The winner, chosen at random, is Ms. Alison Tutt, Laboratory Manager in the Tenovus Research Laboratory, Cancer Sciences Division at Southampton University, United Kingdom.

"The BioTek Epoch equipment will be an enormous aid to the researchers in the laboratory," notes Ms. Tutt. "It should speed up procedures that are already in house and will replace an old plate reader and dot matrix printer." The Tenovus Research Laboratory investigates CD20 cancer cells and how antibodies effect lymphoma treatment. Currently, they seek to improve upon Rituximab effects through an increased understanding of the underlying mechanisms and biology. The Epoch will be used for the assessment of protein and DNA concentrations and purity.

The complete Epoch Multi-Volume Spectrophotometer System consists of the Epoch Microplate Spectrophotometer and the unique Take3^TM Multi-Volume Plate. The monochromator-based Epoch measures absorbance from 200-999 nm in 6- to 384-well microplates. Along with endpoint readings for nucleic acid and protein quantification, Epoch can also perform wavelength scanning, kinetic and well area scanning measurements. The unique Take3 accessory measures up to sixteen 2 µL samples, two BioCells^TM or a standard cuvette. Pre-programmed and user-generated programs, as well as data output, are controlled via Gen5^TM Data Analysis Software.

Congratulations to Ms. Tutt, and the entire Tenovus Research Laboratory!

BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. BioTek instrumentation is used to aid in the advancement of life science research, facilitate the drug discovery process and to enable cost-effective quantification of disease relevant molecules in the clinic.